{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T23:43:49Z","timestamp":1780962229828,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40119-025-00407-7","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T18:06:44Z","timestamp":1745518004000},"page":"231-247","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimizing Blood Pressure Control: A Randomized Comparative Trial of Losartan\/Chlorthalidone vs. Losartan\/Hydrochlorothiazide"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04927299","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Isabel E.","family":"Rucker-Joerg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7868-667X","authenticated-orcid":false,"given":"Ernesto G.","family":"Cardona-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5900-2284","authenticated-orcid":false,"given":"Francisco G.","family":"Padilla-Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3046-2973","authenticated-orcid":false,"given":"Rodrigo","family":"Suarez-Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2613-1714","authenticated-orcid":false,"given":"Yulia","family":"Romero-Antonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4954-0292","authenticated-orcid":false,"given":"Emmanuel","family":"Canales-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7012-3831","authenticated-orcid":false,"given":"Kevin F.","family":"Rios-Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8578-3742","authenticated-orcid":false,"given":"Ileana C.","family":"Rodr\u00edguez-Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7412-6499","authenticated-orcid":false,"given":"Jorge","family":"Gonz\u00e1lez-Canudas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"issue":"8","key":"407_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0289546","volume":"18","author":"W Kibone","year":"2023","unstructured":"Kibone W, Bongomin F, Okot J, et al. High blood pressure prevalence, awareness, treatment, and blood pressure control among Ugandans with rheumatic and musculoskeletal disorders. PLoS ONE. 2023;18(8): e0289546. https:\/\/doi.org\/10.1371\/journal.pone.0289546.","journal-title":"PLoS ONE"},{"issue":"12","key":"407_CR2","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstrom M, et al. 2023 ESH guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874\u20132071. https:\/\/doi.org\/10.1097\/HJH.0000000000003480.","journal-title":"J Hypertens"},{"issue":"11","key":"407_CR3","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41569-021-00559-8","volume":"18","author":"B Zhou","year":"2021","unstructured":"Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021;18(11):785\u2013802. https:\/\/doi.org\/10.1038\/s41569-021-00559-8.","journal-title":"Nat Rev Cardiol"},{"key":"407_CR4","doi-asserted-by":"publisher","first-page":"s169","DOI":"10.21149\/14779","volume":"65","author":"I Campos-Nonato","year":"2023","unstructured":"Campos-Nonato I, Oviedo-Solis C, Vargas-Meza J, et al. Prevalencia, tratamiento y control de la hipertension arterial en adultos mexicanos: resultados de la Ensanut 2022. Salud Publica Mex. 2023;65:s169\u201380. https:\/\/doi.org\/10.21149\/14779.","journal-title":"Salud Publica Mex"},{"issue":"6","key":"407_CR5","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","volume":"42","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206\u201352. https:\/\/doi.org\/10.1161\/01.HYP.0000107251.49515.c2.","journal-title":"Hypertension"},{"key":"407_CR6","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.arr.2016.01.007","volume":"26","author":"TW Buford","year":"2016","unstructured":"Buford TW. Hypertension and aging. Ageing Res Rev. 2016;26:96\u2013111. https:\/\/doi.org\/10.1016\/j.arr.2016.01.007.","journal-title":"Ageing Res Rev"},{"issue":"7","key":"407_CR7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s11886-022-01706-4","volume":"24","author":"D Canoy","year":"2022","unstructured":"Canoy D, Nazarzadeh M, Copland E, et al. How much lowering of blood pressure is required to prevent cardiovascular disease in patients with and without previous cardiovascular disease? Curr Cardiol Rep. 2022;24(7):851\u201360. https:\/\/doi.org\/10.1007\/s11886-022-01706-4.","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"407_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jch.13426","volume":"21","author":"DJ DiPette","year":"2019","unstructured":"DiPette DJ, Skeete J, Ridley E, et al. Fixed-dose combination pharmacologic therapy to improve hypertension control worldwide: clinical perspective and policy implications. J Clin Hypertens (Greenwich). 2019;21(1):4\u201315. https:\/\/doi.org\/10.1111\/jch.13426.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"3","key":"407_CR9","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.hipert.2024.03.004","volume":"41","author":"FJ Morales-Olivas","year":"2024","unstructured":"Morales-Olivas FJ. Diuretics use in the management of hypertension. Hipertens Riesgo Vasc. 2024;41(3):186\u201393. https:\/\/doi.org\/10.1016\/j.hipert.2024.03.004.","journal-title":"Hipertens Riesgo Vasc"},{"issue":"2","key":"407_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.acmx.2017.06.001","volume":"88","author":"S Gonzalez-Gomez","year":"2018","unstructured":"Gonzalez-Gomez S, Melendez-Gomez MA, Lopez-Jaramillo P. Fixed-dose combination therapy to improve hypertension treatment and control in Latin America. Arch Cardiol Mex. 2018;88(2):129\u201335. https:\/\/doi.org\/10.1016\/j.acmx.2017.06.001.","journal-title":"Arch Cardiol Mex"},{"issue":"10150","key":"407_CR11","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(18)31814-2","volume":"392","author":"SP Kishore","year":"2018","unstructured":"Kishore SP, Salam A, Rodgers A, Jaffe MG, Frieden T. Fixed-dose combinations for hypertension. Lancet. 2018;392(10150):819\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(18)31814-2.","journal-title":"Lancet"},{"issue":"6","key":"407_CR12","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269\u2013324. https:\/\/doi.org\/10.1161\/HYP.0000000000000066.","journal-title":"Hypertension"},{"key":"407_CR13","unstructured":"Guideline for the pharmacological treatment of hypertension in adults. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO."},{"issue":"7","key":"407_CR14","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1161\/CIRCRESAHA.118.313294","volume":"124","author":"G Mancia","year":"2019","unstructured":"Mancia G, Rea F, Corrao G, Grassi G. Two-drug combinations as first-step antihypertensive treatment. Circ Res. 2019;124(7):1113\u201323. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.313294.","journal-title":"Circ Res"},{"issue":"1","key":"407_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/hr.2012.143","volume":"36","author":"BJ Kwon","year":"2013","unstructured":"Kwon BJ, Jang SW, Choi KY, et al. Comparison of the efficacy between hydrochlorothiazide and chlorthalidone on central aortic pressure when added on to candesartan in treatment-naive patients of hypertension. Hypertens Res. 2013;36(1):79\u201384. https:\/\/doi.org\/10.1038\/hr.2012.143.","journal-title":"Hypertens Res"},{"key":"407_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40885-018-0089-1","volume":"24","author":"RT Mehta","year":"2018","unstructured":"Mehta RT, Pareek A, Purkait I. Chlorthalidone, not hydrochlorothiazide, is the right diuretic for comparison. Clin Hypertens. 2018;24:4. https:\/\/doi.org\/10.1186\/s40885-018-0089-1.","journal-title":"Clin Hypertens"},{"key":"407_CR17","unstructured":"FDA. Hypertension: Developing fixed-combination drug products for treatment guidance for industry. U.S. Department of Health and Human Services. 2018."},{"issue":"6","key":"407_CR18","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension. 2020;75(6):1334\u201357. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15026.","journal-title":"Hypertension"},{"issue":"4","key":"407_CR19","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1097\/HJH.0000000000001647","volume":"36","author":"WC Cushman","year":"2018","unstructured":"Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, et al. A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension. J Hypertens. 2018;36(4):947\u201356.","journal-title":"J Hypertens"},{"key":"407_CR20","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212531","volume":"7","author":"C Guerrero-Garcia","year":"2018","unstructured":"Guerrero-Garcia C, Rubio-Guerra AF. Combination therapy in the treatment of hypertension. Drugs Context. 2018;7: 212531. https:\/\/doi.org\/10.7573\/dic.212531.","journal-title":"Drugs Context"},{"issue":"1","key":"407_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/01.HYP.0000103632.19915.0E","volume":"43","author":"BL Carter","year":"2004","unstructured":"Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension. 2004;43(1):4\u20139. https:\/\/doi.org\/10.1161\/01.HYP.0000103632.19915.0E.","journal-title":"Hypertension"},{"issue":"6","key":"407_CR22","doi-asserted-by":"publisher","first-page":"447","DOI":"10.7326\/0003-4819-158-6-201303190-00004","volume":"158","author":"IA Dhalla","year":"2013","unstructured":"Dhalla IA, Gomes T, Yao Z, et al. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. Ann Intern Med. 2013;158(6):447\u201355. https:\/\/doi.org\/10.7326\/0003-4819-158-6-201303190-00004.","journal-title":"Ann Intern Med"},{"issue":"1","key":"407_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/CRD.0b013e3181c61b52","volume":"18","author":"KM Neff","year":"2010","unstructured":"Neff KM, Nawarskas JJ. Hydrochlorothiazide versus chlorthalidone in the management of hypertension. Cardiol Rev Jan-Feb. 2010;18(1):51\u20136. https:\/\/doi.org\/10.1097\/CRD.0b013e3181c61b52.","journal-title":"Cardiol Rev Jan-Feb"},{"issue":"8","key":"407_CR24","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1097\/HJH.0000000000002088","volume":"37","author":"M Burnier","year":"2019","unstructured":"Burnier M, Bakris G, Williams B. Redefining diuretics use in hypertension: why select a thiazide-like diuretic? J Hypertens. 2019;37(8):1574\u201386. https:\/\/doi.org\/10.1097\/HJH.0000000000002088.","journal-title":"J Hypertens"},{"issue":"7","key":"407_CR25","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1093\/ajh\/hpac048","volume":"35","author":"ME Ernst","year":"2022","unstructured":"Ernst ME, Fravel MA. Thiazide and the thiazide-like diuretics: review of hydrochlorothiazide, chlorthalidone, and indapamide. Am J Hypertens. 2022;35(7):573\u201386. https:\/\/doi.org\/10.1093\/ajh\/hpac048.","journal-title":"Am J Hypertens"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00407-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-025-00407-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00407-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T02:48:41Z","timestamp":1747450121000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-025-00407-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["407"],"URL":"https:\/\/doi.org\/10.1007\/s40119-025-00407-7","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Isabel E. Rucker-Joerg, Ernesto G. Cardona-Mu\u00f1oz, Francisco G. Padilla-Padilla, and Rodrigo Suarez-Otero confirm that they have no conflicts of interest to declare. Jorge Alejandro Gonzalez Canudas, Emmanuel Canales-V\u00e1zquez, Yulia Romero-Antonio, Kevin F. Rios-Brito, and Ileana Cristina Rodriguez Vazquez are employees of Laboratorios Silanes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was carried out entirely in accordance with the legal provisions of the General Health Law of the United Mexican States and with the ethical principles emanating from the eighteenth World Medical Assembly in Helsinki, Finland, in 1964 and its respective amendments, concerning medical research on human beings. It was approved by the Research Ethics Committee of Investigaci\u00f3n Biom\u00e9dica para el Desarrollo de F\u00e1rmacos S.A. de C.V. (Protocol approval number: CEI-000002). Study regulatory adherence: Ministry of Health in Mexico: Federal Commission for the Protection against Sanitary Risks (COFEPRIS) Approval Number: 223300410A0096\/2021.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}